Haemoglobinopathies

Researchers in France and Italy have developed a multiplex base editing strategy that simultaneously targets two BCL11A gene enhancers to treat sickle...

Haemoglobinopathies

Beta-Thalassemia, (NCT06717932)
Sponsors:
CorrectSequence Therapeutics Co., Ltd

IND Enabling

Phase I

Phase II

Phase III

Beta-Thalassemia, (NCT06685536)
Sponsors:
CorrectSequence Therapeutics Co., Ltd

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, (NCT07000318)
Sponsors:
Children's Hospital of Fudan University

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT06506461)
Sponsors:
St. Jude Children's Research Hospital

IND Enabling

Phase I

Phase II

Phase III

Beta-Thalassemia, BT, (NCT06024876)
Sponsors:
CorrectSequence Therapeutics Co., Ltd

IND Enabling

Phase I

Phase II

Phase III

Transfusion-dependent Beta-Thalassemia, TDT, (NCT06065189)
Sponsors:
Children's Hospital of Fudan University

IND Enabling

Phase I

Phase II

Phase III

Transfusion-dependent Beta-Thalassemia, TDT, (NCT06291961)
Sponsors:
CorrectSequence Therapeutics Co., Ltd

IND Enabling

Phase I

Phase II

Phase III

Beta-Thalassemia, BT, (NCT06328764)
Sponsors:
CorrectSequence Therapeutics Co., Ltd

IND Enabling

Phase I

Phase II

Phase III